Pharma Index Hits 52-Week High As Sun Pharma, Glenmark and Lupin Gain Up To 3%

Pharmaceutical stocks were in strong demand on Wednesday, even as the broader market remained subdued. The Nifty Pharma index rose 1.6% intraday to 23,492.55, hitting a 52-week high.

Over the last 2 trading sessions, the pharma index has gained 3.3%, while the Nifty 50 declined 0.41%, showing clear sector outperformance.

Index Crosses Previous Highs

The Nifty Pharma index moved above its earlier peak of 23,418.20, recorded in January 2025. It is now close to its all-time high of 23,907.90, touched in October 2024.

Key Stocks Leading The Rally

Sun Pharmaceutical Industries, Glenmark Pharmaceuticals and Lupin gained around 3% each in intraday trade.

Other stocks such as Piramal Pharma, Mankind Pharma, Biocon, Aurobindo Pharma, Ipca Laboratories, Alkem Laboratories and Granules India rose about 2%. Meanwhile, Torrent Pharmaceuticals, Laurus Labs, Sai Life Sciences and Senores Pharmaceuticals touched their respective all-time highs.

Strong Domestic Demand Lifts Sentiment

Pharma stocks gained momentum after data showed steady growth in the Indian Pharmaceutical Market (IPM) for December, which supported investor confidence.

Biosecure Act Creates New Opportunities

The US Biosecure Act, signed in December, restricts US federal agencies from sourcing biotech products from certain Chinese companies. This opens up opportunities for Indian CDMO players.

Companies such as Divi’s Laboratories, Piramal Pharma and Laurus Labs are seen as key beneficiaries due to their global capabilities.

Also Read: Government Leans on Dividends as IDBI Bank Sale Becomes Key to FY26 Capital Receipts!

Conclusion

Pharma stocks are outperforming the broader market due to strong domestic demand, a positive earnings outlook, and fresh opportunities in the CDMO space. The sector remains firmly in focus for investors.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.